Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yaounde Central Hospital
Background: The rapid beneficial effects of Empagliflozin on cardiovascular mortality and hospitalizations rates for heart failure according to the Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial raise some question in the mechanism of myocardial action. The investigators conducted this study in a population of non-diabetic hypertensive patients in order to look for a short-term effect on left ventricular relaxation.
Methods: The investigators carried out a single arm non- randomized clinical trial and assigned patients to receive 25mg of empagliflozin once daily in additional therapy for six weeks at the National Center for Obesity and in the cardiology department of Yaounde Central Hospital in hypertensive patients with cardiac relaxation disorder. The objectives were to evaluate the left ventricular diastolic function and nycthemeral blood pressure profile.
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Grade 1 hypertension
Grade 1 or 2 relaxation abnormalities (Doppler E/A ratio \<1)
Unchanged antihypertensive treatment for at least 12 weeks
You may not be if
Diabetes mellitus
eGFR \< 60 mL/min/1,73 m²
Mitral stenosis
Atrial fibrillation
Alanine transferase above 2N
Clareo Health | Short Term Effect of Empagliflozin in Hypertension
